Vaccines & Immunology

mRNA platforms, boosters, monoclonals, and immune‑system science.

  • 18 Tracked terms
  • Last 30 days Feed window

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Vaccines & Immunology


insilico.com > news > lgv150926en-ai-driven-longevity-vaccines

Insilico Launches AI-driven Longevity Vaccines Research for Aging-related Diseases and Human Longevity

2+ hour, 28+ min ago   (186+ words) The program applies generative AI and programmable RNA medicine to design single-administration, self-limiting in vivo cell therapies that clear the earliest culprit cells of age-related disease. a research initiative developing treatments that direct a patient’s own immune cells to eliminate…...


chemistryworld.com > news > does-the-discovery-of-a-new-coronavirus-upend-the-covid-19-lab-leak-hypothesis > 4024170.article

Does the discovery of a new coronavirus upend the Covid-19 lab-leak hypothesis?

3+ hour, 6+ min ago   (308+ words) The furin cleavage site that makes Sars-CoV-2 more infectious has now been discovered in a virus found in Parnell’s moustached bat that lives in the Americas A new coronavirus discovered in a Brazilian bat provides more support for the theory…...


eu.36kr.com > en > p > 3984054595360643

Exclusive Interview with Nobel Laureate Katalin Karikó: 40 Years Pioneering in mRNA's No-Man's-Land - My Unwavering Belief in the Groundbreaking Significance of My mRNA Research

5+ hour, 58+ min ago   (1362+ words) When the entire world turned its attention to mRNA vaccines and hailed them as the saviors against the COVID-19 pandemic, the woman who laid their scientific cornerstone behind the scenes had already walked alone on a little-trodden, widely questioned path…...


federalregister.gov > documents > 09/15/2026 > 2026-18877 > prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-engineered

Prospective Grant of an Exclusive Patent License: Development and Commercialization of Engineered Cell Therapies for the Treatment of HPV 16 E6-Expressing Cancers

7+ hour, 42+ min ago   (419+ words) A Notice by the National Institutes of Health on 09/15/2026 This document has a comment period that ends in 15 days. (09/30/2026) View Comment Instructions This PDF is FR Doc. 2026-18877 as it appeared on Public Inspection on 09/14/2026 at 8:45 am. National Institutes of Health,…...


eurekalert.org > multimedia > 1151864

Lung-targeting mRNA-lipid nanoparticles for the treatment of acute lung injury

17+ hour, 1+ min ago   (77+ words) (IMAGE) eurekalert.org Read more about the new world-class SUNY discoveries that are available for licensing at SUNY TechConnect. The Research Foundation offers numerous pathways to translate SUNY innovation into economic development opportunities. State University of New York Mahfuz Miah…...


news.uq.edu.au > 2026-09-uq-vaccinologist-backed-life-sciences-queensland

UQ vaccinologist backed by Life Sciences Queensland

5+ hour, 15+ min ago   (91+ words) A University of Queensland virologist and vaccinologist received the top honour at the Life Science Queensland Gene Awards 2026 to advance vaccine discovery and translation. Dr Chris McMillan received the inaugural SQ Bio-Innovation Bursary to support his research into innovative vaccine…...


ataraxis.ai > causal-ai-chemotherapy-benefit

Causal multi-modal AI predicts who benefits from chemotherapy — and who will not

19+ hour, 22+ min ago   (510+ words) Authors: Dhruva Biswas and Krzysztof J. Geras AI-enabled perception of how treatment choice shapes patient trajectories. Causal multi-modal AI turns routine pathology and clinical data into personalized estimates of chemosensitivity, separating risk of recurrence from treatment benefit to help direct chemotherapy…...


finance.yahoo.com > healthcare > articles > ataraxis-ai-publishes-landmark-studies-150000013.html

Ataraxis AI Publishes Landmark Studies Showing Causal AI Predicts Chemotherapy Benefit in Multiple Solid Tumors

1+ day, 3+ hour ago   (324+ words) NEW YORK, September 14, 2026--(BUSINESS WIRE)--Ataraxis AI, a company building clinical AI tools to personalize cancer care, today announced scientific breakthroughs and validation results of Ataraxis's AI models. Ataraxis developed breakthrough causal AI methods that learn from large-scale, longitudinal data…...